Navigation Links
New drug shows promise for those with clotting disorders: McMaster researcher
Date:12/6/2009

Hamilton, ON. Dec. 6, 2009 A new study provides welcome news for patients with a common clotting disorder known as venous thromboembolism (VTE).

The condition is estimated to impact 62,000 Canadians and half-a-million Americans every year, and occurs when an abnormal clot forms in a vein and restricts the flow of blood, causing pain and swelling. In some cases, the clot may detach from its point of origin and travel through the heart to the lungs, causing a potentially fatal condition known as a pulmonary embolism.

Currently, patients with VTE are treated with a blood thinner known as warfarin, which has many burdensome interactions with other medications and foods and requires frequent monitoring of the dosage.

However, this study published today shows that an oral drug called dabigatran etexilate, which does not have these disadvantages, is as safe and effective as warfarin for combating VTE.

To compare the two drugs, an international team of researchers lead by Sam Schulman, a professor of medicine of the Michael G. DeGroote School of Medicine, who conducted a randomized, double-blind trial of 2,539 patients with acute VTE.

Today, Schulman is scheduled to present this study to the annual conference of the American Society of Hematology in New Orleans, LA, and the New England Journal of Medicine will post the study on its web site. The study will be published in the Dec. 10 edition of the New England Journal of Medicine.

For six months, roughly half of the patients in the trial (1,274) were given a fixed dose of 150 mg of dabigatran etexilate twice daily, while the other half (1,265 patients) were given warfarin once daily.

The improvement seen in both groups from the treatments was similar. After six months of treatment, only 2.4 percent of the dabigatran etexilate group (30 patients) and 2.1 percent of the warfarin group (27 patients) experienced recurrent VTE.

The safety of the two drugs was also comparable. In the dabigatran etexilate arm, 205 patients experienced bleeding (including 20 patients with major bleeding) versus 277 patients in the warfarin arm (including 24 with major bleeding). Other possible side effects, including death, acute coronary syndromes, and abnormalities in liver function tests, were infrequent in the two groups.

"We are excited by these findings and feel that they will change the standard of care for venous thromboembolism, which affects a large number of our patients," said Schulman, a physician with the thrombosis service of Hamilton Health Sciences. "This study found that dabigatran is a safe and effective anticoagulant that does not require the routine monitoring or dose adjustments that are necessary with warfarin. In other words, patients can receive the same results in a more convenient manner."


'/>"/>

Contact: Susan Emigh
emighs@mcmaster.ca
905-518-3642
McMaster University
Source:Eurekalert

Related medicine news :

1. Congress Has Allowed Most Previous Medicare Cuts to Take Effect, New Study Shows
2. NYU Langone Medical Center Study Shows VNS Therapy is a Safe and Effective Treatment for Refractory Epilepsy
3. New Actuarial Analysis Shows Senate Bill Would Significantly Raise Premiums
4. New Hepatitis C Treatment Shows Promise
5. Report shows CIMT may improve arm use in children with hemiplegic cerebral palsy
6. Alcohol companies target youths with magazine ads, new study shows
7. Study shows modest improvement in advanced lung cancer overall survival rates
8. New Survey Shows Overwhelming Support Among Latinos for Health Care Reform That Includes Public Option
9. Brain scan study shows cocaine abusers can control cravings
10. Study shows new brain connections form rapidly during motor learning
11. Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... 23, 2017 , ... The Pharmacy and Medically Underserved Areas ... original co-sponsorship of nearly one-quarter of the U.S. House of Representatives. The Senate ... Drug Stores (NACDS) strongly backs the legislation. , “NACDS thanks for their leadership ...
(Date:1/24/2017)... Ariz. (PRWEB) , ... January 23, 2017 , ... ... recently analyzed statistics from 140 Buzzies users who entered metrics into the product’s ... earlier clinical data. The new data showed that within just 30 seconds of ...
(Date:1/23/2017)... ... , ... PKF O’Connor Davies , LLP, the nation’s 26th largest accounting ... Firm, will participate in the 40th Annual "Empire State Building Run Up" on Feb. ... steps, a vertical distance equal to about a fifth of a mile, to reach ...
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... Wooden and plastic balance boards have been ... and improve balance. Kumo Board is the first and only balance board to ... to be soft and rigid at the same time as well as skill-level adjustable for ...
(Date:1/23/2017)... ... 23, 2017 , ... METTLER TOLEDO has announced the availability ... Simple PAT Tools . , Crystallization is a common step used ... Chemists now spend more time developing better intermediate and final crystallization steps. ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... -- The global peripheral I.V. catheter market accounted for ... to grow at a CAGR of 6.0% during 2016-2022. ... share in the global market between the two types ... hospital segment accounted for the highest share in the ... I.V. catheter market is witnessing high growth rate, due ...
(Date:1/23/2017)... , Jan. 23, 2017  HOPE BIOSCIENCES ... rights to develop and commercialize nuc -gemcitabine™ ... a Korean pharmaceutical company. nuc ... aptamer against surface nucleolin found on many cancer ... Unlike ADCs (antibody drug conjugates) or SMDCs (small ...
(Date:1/23/2017)... 23, 2017  Based on its recent analysis ... recognizes Ansell, a global leader in protection solutions, ... of the Year Award. Ansell,s comprehensive product portfolio, ... global footprint have placed it in a position ... The Company,s established product line and robust innovation ...
Breaking Medicine Technology: